- Article
Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2
- Jorge Hernández-Bello,
- José Javier Morales-Núñez,
- Andrea Carolina Machado-Sulbarán,
- Saúl Alberto Díaz-Pérez,
- Paola Carolina Torres-Hernández,
- Paulina Balcázar-Félix,
- Jesús Alberto Gutiérrez-Brito,
- José Alvaro Lomelí-Nieto and
- José Francisco Muñoz-Valle
This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people (1...